Study Finds Mylan's 'Biosimilar' Drug Comparable to Roche Cancer Medicine
June 03 2016 - 06:00PM
Dow Jones News
CHICAGO—Researchers said a drug being developed by Mylan
Pharmaceuticals Inc. proved comparable to Roche Holding AG's
Herceptin in a clinical trial, a new milestone in the effort to
bring cheaper versions of some of biotechnology's best-known cancer
drugs to the market.
In a study involving a total of 500 patients, Mylan's drug,
called Myl-1401O, was shown to be essentially equivalent in safety
and effectiveness to Herceptin, a multibillion-dollar medicine that
in the past two decades has transformed treatment for about 25% of
breast cancer patients.
Mylan's drug is a so-called biosimilar—the industry's term for a
copy of a biotechnology drug. The copy "has the potential to meet
the need for an affordable treatment option" for women diagnosed
with what is known as Her2-positive breast cancer, said Hope S.
Rugo, lead author of the report and professor of medicine at
University of California San Francisco. "We haven't been able to
deliver lifesaving therapies around the world because of cost," Dr.
Rugo said.
In a statement, Rajiv Malik, president of Mylan, said, "There is
an urgent unmet need for more affordable versions of biologic
products." But the company declined to discuss its pricing plans.
Mylan is developing the drug in collaboration with Biocon Ltd. of
India, where the Herceptin copy is already on the market.
How much insurers may ultimately save with biosimilars is
unclear. Unless there are multiple biosimilars for a single branded
drug, prices are expected to drop by only 15% to 30% from the
branded drug's price. Another question is whether doctors and
patients will be willing to switch to a biosimilar from Herceptin,
an iconic breast cancer treatment.
Jonathan D. Rockoff contributed to this article.
Write to Ron Winslow at ron.winslow@wsj.com and Peter Loftus at
peter.loftus@wsj.com
(END) Dow Jones Newswires
June 03, 2016 17:45 ET (21:45 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
Mylan NV (NASDAQ:MYL)
Historical Stock Chart
From Feb 2024 to Mar 2024
Mylan NV (NASDAQ:MYL)
Historical Stock Chart
From Mar 2023 to Mar 2024